Baseline characteristics (N = 915)
| . | Median (range) or n (%) . |
|---|---|
| Age, y | 66 (29-89) |
| Males/females | 540 (59)/375 (41) |
| NYHA class | |
| 1 | 223 (24.4) |
| 2 | 446 (48.7) |
| 3 | 108 (11.8) |
| 4 | 4 (0.1) |
| Unrecorded | 134 (15.0) |
| ECOG score | |
| 0 | 205 (22.4) |
| 1 | 363 (40.0) |
| 2 | 259 (28.3) |
| 3 | 49 (5.3) |
| 4 | 0 |
| Unrecorded | 39 (4.0) |
| Cardiac involvement | 653 (71.4) |
| NT-proBNP, ng/L | 2 228 (29-93 776) |
| High-sensitivity cardiac troponin T, ng/L | 54 (1-458) |
| Mayo stage | |
| I | 144 (15.7) |
| II | 302 (33) |
| III, NT-proBNP ≤ 8500 ng/L | 344 (37.6) |
| III, NT-proBNP > 8500 ng/L | 125 (13.7) |
| Systolic blood pressure, mm Hg | 118 (63-198) |
| LV wall thickness, mm | 13 (6-23) |
| LV ejection fraction, % | 58 (11-80) |
| Renal involvement | 623 (68.1) |
| Serum creatinine, μmol/L | 97.5 (26-1124) |
| GFR, mL/min | 64 (3-100) |
| Proteinuria, g/24 h | 3.14 (0.08-36.05) |
| Liver involvement | 124 (13.5) |
| Serum bilirubin, μmol/L | 6 (1-449) |
| ALP, U/L | 90 (26-2142) |
| Soft tissue involvement | 124 (13.5) |
| Peripheral nerve involvement | 57 (6.2) |
| Autonomic nerve involvement | 53 (5.8) |
| GI involvement | 28 (3.0) |
| No. of involved organs | 2 (1-5) |
| Involved light chains | |
| κ | 186 (20.3) |
| λ | 680 (74.3) |
| No monoclonal light chain excess | 49 (5.4) |
| Median dFLC, mg/L | 180 (0-15898) |
| IgG/IgA/IgM/IgD/light chain/no detectable serum paraprotein | 239 (26.1)/93(10.2)/26 (2.8)/4(0.04)/61(6.7)/492 (53.8) |
| Median serum monoclonal protein, g/L | 4 |
| Duration from diagnosis to treatment initiation, d | 27 (0-98) |
| . | Median (range) or n (%) . |
|---|---|
| Age, y | 66 (29-89) |
| Males/females | 540 (59)/375 (41) |
| NYHA class | |
| 1 | 223 (24.4) |
| 2 | 446 (48.7) |
| 3 | 108 (11.8) |
| 4 | 4 (0.1) |
| Unrecorded | 134 (15.0) |
| ECOG score | |
| 0 | 205 (22.4) |
| 1 | 363 (40.0) |
| 2 | 259 (28.3) |
| 3 | 49 (5.3) |
| 4 | 0 |
| Unrecorded | 39 (4.0) |
| Cardiac involvement | 653 (71.4) |
| NT-proBNP, ng/L | 2 228 (29-93 776) |
| High-sensitivity cardiac troponin T, ng/L | 54 (1-458) |
| Mayo stage | |
| I | 144 (15.7) |
| II | 302 (33) |
| III, NT-proBNP ≤ 8500 ng/L | 344 (37.6) |
| III, NT-proBNP > 8500 ng/L | 125 (13.7) |
| Systolic blood pressure, mm Hg | 118 (63-198) |
| LV wall thickness, mm | 13 (6-23) |
| LV ejection fraction, % | 58 (11-80) |
| Renal involvement | 623 (68.1) |
| Serum creatinine, μmol/L | 97.5 (26-1124) |
| GFR, mL/min | 64 (3-100) |
| Proteinuria, g/24 h | 3.14 (0.08-36.05) |
| Liver involvement | 124 (13.5) |
| Serum bilirubin, μmol/L | 6 (1-449) |
| ALP, U/L | 90 (26-2142) |
| Soft tissue involvement | 124 (13.5) |
| Peripheral nerve involvement | 57 (6.2) |
| Autonomic nerve involvement | 53 (5.8) |
| GI involvement | 28 (3.0) |
| No. of involved organs | 2 (1-5) |
| Involved light chains | |
| κ | 186 (20.3) |
| λ | 680 (74.3) |
| No monoclonal light chain excess | 49 (5.4) |
| Median dFLC, mg/L | 180 (0-15898) |
| IgG/IgA/IgM/IgD/light chain/no detectable serum paraprotein | 239 (26.1)/93(10.2)/26 (2.8)/4(0.04)/61(6.7)/492 (53.8) |
| Median serum monoclonal protein, g/L | 4 |
| Duration from diagnosis to treatment initiation, d | 27 (0-98) |
ALP, alkaline phosphatase; ECOG, Eastern Cooperative Oncology Group; GFR, glomerular filtration rate; GI, gastrointestinal; Ig, immunoglobulin; LV, left ventricular; NYHA, New York Heart Association.